Metformine Viatris

Metformin, the active ingredient in Metformine Viatris, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus, improving glycemic control when used alongside diet and exercise. It works by decreasing hepatic glucose production and increasing peripheral insulin sensitivity.

GNH USA supplies Metformine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Metformine Viatris (metformin) is indicated for conditions within the glucose‑regulation pathway, primarily type 2 diabetes and related disorders.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Gestational diabetes mellitus: assists in achieving target blood glucose when diet alone is insufficient. - Prediabetes (impaired glucose tolerance): reduces the risk of progression to overt diabetes by improving insulin sensitivity.

Metformine Viatris may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angioedema.

Before prescribing Metformine Viatris, clinicians should evaluate patient‑specific risk factors and monitor therapy regularly. - Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic function: contraindicated in patients with significant liver disease. - Lactic acidosis risk: avoid in conditions predisposing to hypoxia or acidosis. - Monitoring: check HbA1c, renal and hepatic labs periodically. - Drug interactions: review concomitant medications that may affect metformin clearance. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture and heat.

Metformine Viatris can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate acute renal failure and lactic acidosis. - Acute heart failure: increases risk of lactic acidosis. - Severe renal impairment: markedly reduces drug clearance. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycemia; dose adjustment may be needed. - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal function and electrolyte balance. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - Oral contraceptives: may slightly increase metformin levels.